Adaptive Biotechnologies annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies Debt-to-Equity Ratio Growth & History (ADPT)
Adaptive Biotechnologies's debt-to-equity ratio was 0.96 for fiscal 2025.
View full Adaptive Biotechnologies company overviewAdaptive Biotechnologies annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.96 | −0.14 | −12.47% |
| 2024 | 2024-12-31 | 1.10 | 0.35 | +47.65% |
| 2023 | 2023-12-31 | 0.74 | 0.24 | +47.97% |
| 2022 | 2022-12-31 | 0.50 | 0.32 | +171.76% |
| 2021 | 2021-12-31 | 0.19 | 0.04 | +27.48% |
| 2020 | 2020-12-31 | 0.15 | 0.08 | +126.37% |
| 2019 | 2019-12-31 | 0.06 | — | — |
Adaptive Biotechnologies quarterly debt-to-equity ratio
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.53 | −0.68 | −56.36% |
| Q1 2026 | 2026-03-31 | 0.96 | −0.20 | −16.88% |
| Q4 2025 | 2025-12-31 | 0.96 | −0.14 | −12.47% |
| Q3 2025 | 2025-09-30 | 1.05 | 0.04 | +4.15% |
| Q2 2025 | 2025-06-30 | 1.21 | 0.28 | +29.49% |
| Q1 2025 | 2025-03-31 | 1.16 | 0.33 | +39.57% |
| Q4 2024 | 2024-12-31 | 1.10 | 0.35 | +47.65% |
| Q3 2024 | 2024-09-30 | 1.00 | 0.36 | +56.96% |
| Q2 2024 | 2024-06-30 | 0.94 | 0.68 | +258.27% |
| Q1 2024 | 2024-03-31 | 0.83 | 0.58 | +232.50% |
| Q4 2023 | 2023-12-31 | 0.74 | 0.24 | +47.97% |
| Q3 2023 | 2023-09-30 | 0.64 | 0.42 | +185.96% |
| Q2 2023 | 2023-06-30 | 0.26 | 0.05 | +21.68% |
| Q1 2023 | 2023-03-31 | 0.25 | 0.04 | +21.57% |
| Q4 2022 | 2022-12-31 | 0.50 | 0.32 | +171.76% |
| Q3 2022 | 2022-09-30 | 0.22 | 0.05 | +28.71% |
| Q2 2022 | 2022-06-30 | 0.21 | 0.06 | +37.11% |
| Q1 2022 | 2022-03-31 | 0.21 | 0.07 | +49.56% |
| Q4 2021 | 2021-12-31 | 0.19 | 0.04 | +27.48% |
| Q3 2021 | 2021-09-30 | 0.17 | 0.11 | +190.51% |
| Q2 2021 | 2021-06-30 | 0.16 | 0.07 | +81.56% |
| Q1 2021 | 2021-03-31 | 0.14 | 0.07 | +98.92% |
| Q4 2020 | 2020-12-31 | 0.15 | 0.08 | +126.37% |
| Q3 2020 | 2020-09-30 | 0.06 | 0.02 | +49.38% |
| Q2 2020 | 2020-06-30 | 0.09 | — | — |
| Q1 2020 | 2020-03-31 | 0.07 | — | — |
| Q4 2019 | 2019-12-31 | 0.06 | — | — |
| Q3 2019 | 2019-09-30 | 0.04 | — | — |
Adaptive Biotechnologies debt-to-equity ratio trends
Over the last five fiscal years, Adaptive Biotechnologies's debt-to-equity ratio increased from 0.15 to 0.96, a change of 0.82. The latest reported quarter, Q2 2026, shows 0.53.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adaptive Biotechnologies source filings ↗